Organon (OGN) Free Cash Flow Growth (1y) (2021 - 2026)
Organon (OGN) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -12.19% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -22.41% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 82.57% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 376.81% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 125.17% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 28.86% |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | -64.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -64.09% |
| Mar 31, 2026 | 337.21% |
| Dec 31, 2025 | -71.34% |
| Sep 30, 2025 | 120.20% |
| Jun 30, 2025 | -39.67% |
| Mar 31, 2025 | 43.33% |
| Dec 31, 2024 | 5.35% |
| Sep 30, 2024 | -51.94% |
| Jun 30, 2024 | 781.82% |
| Mar 31, 2024 | -55.88% |
| Dec 31, 2023 | 55.88% |
| Sep 30, 2023 | -21.37% |
| Jun 30, 2023 | -141.51% |
| Mar 31, 2023 | -24.44% |
| Dec 31, 2022 | 1,800.00% |
| Sep 30, 2022 | -21.08% |
| Jun 30, 2022 | -72.54% |
| Mar 31, 2022 | -92.87% |
| Dec 31, 2021 | -103.31% |
| Sep 30, 2021 | 78.49% |